Capture Tumor-Derived Exosomes Underlying Several Forms of Cancer
Upwards of 90% of all cancer-related deaths are attributed to metastasis. The spread of cancer from a primary site of origin to other organs or areas of the body. The mechanism of how tumors metastasize to distant sites in the body has long been one of cancer's greatest mysteries. That mystery was recently solved when circulating particles known as tumor-derived exosomes were discovered to be the seeds that promote the spread and growth of cancer metastasis.
Aethlon initiated its tumor-derived exosome research at a time when the medical community believed exosomes were merely cellular debris with no biological function. Today, a therapeutic to address tumor-derived exosomes represents a significant unmet need in cancer care. Aethlon has demonstrated that the affinity mechanism of the Hemopurifier® can capture tumor-derived exosomes and exosomal particles underlying several forms of cancer, including breast, ovarian and metastatic melanoma.
Our extended tumor-derived exosome research
Beyond their role in metastasis, researchers have also published mounting evidence that tumor-derived exosomes contribute to tumorigenesis (the formation of cancer), cancer progression, angiogenesis (creation of blood vessels to fuel tumor growth), immune evasion, and resistance to radiation and chemotherapeutic drugs. Recent discoveries also reveal that exosomes may contribute to bacterial and viral pathogenesis, the progression of Alzheimer and Parkinson’s diseases, the spread of prion proteins, and numerous inflammatory conditions.
Status of clinical studies
We are conducting a safety, feasibility and dose-finding clinical trial of the Hemopurifier in Australia in patients with solid tumors who have stable or progressive disease during a regimen that includes pembrolizumab or nivolumab. The primary endpoint of the approximately nine to 18-patient, safety, feasibility and dose-finding trial is safety.
The study consist of three sequential cohorts, with patients receiving one, two, or three Hemopurifier treatments over a one-week period. To date, two of the three cohorts have been completed, and the Data Safety Monitoring Board (DSMB) has reviewed data and reported no safety concerns.
Clinical sites, including Royal Adelaide Hospital in Adelaide, Pindara Private Hospital on the Gold Coast and GenesisCare North Shore in Sydney, are active and enrolling patients as the study progresses.